Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes-Reference-Cited by-同舟云学术

Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes

Published:2022-02 Issue:2 Volume:44 Page:331-348
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Marouf Bushra Hassan^ORCID,Iqbal Zohaib,Mohamad Jamal Basheer,Bashir Bilal^ORCID,Schofield Jonathan,Syed Akheel,Kilpatrick Eric S.,Stefanutti Claudia,Soran Handrean

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference122 articles.

1. Hyperlipidaemia 3 Ed: Diagnosis and Management;Durrington,2007

2. Hypercholesterolaemia—practical information for non-specialists;Soran;Archives of medical science,2018

3. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;European heart journal,2017

4. The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy;Soran;Current opinion in lipidology,2014

5. Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment;Soran;European heart journal,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression;Current Medical Research and Opinion;2024-06-11

2. Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review);International Journal of Molecular Medicine;2024-05-10

3. Treatment of dyslipidemia in metabolic syndrome;Vnitřní lékařství;2024-04-10

4. Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes;Cardiovascular Diabetology;2024-01-03

5. Lipid-lowering in diabetes: An update;Atherosclerosis;2023-10